Table 2.
Construct | Field isolates with equivalent mutation* | Drug susceptibility†
|
Amino acid residue of DHFR domain‡
|
|||||
---|---|---|---|---|---|---|---|---|
Pyr | Cyc | 16 | 51 | 59 | 108 | 164 | ||
Wild type | 3D7, SL/D6 | S | S | Ala | Asn | Cys | Ser | Ile |
A16V§ | Val | Asn | Cys | Ser | Ile | |||
N51I§ | Ala | Ile | Cys | Ser | Ile | |||
C59R§ | Ala | Asn | Arg | Ser | Ile | |||
S108N | HB3 | MR | LR | Ala | Asn | Cys | Asn | Ile |
S108T§ | Ala | Asn | Cys | Thr | Ile | |||
I164L§ | Ala | Asn | Cys | Ser | Leu | |||
A16V + S108T | FAC8, FAC3, UPA, FCB, It.G2.F6 | S | HR | Val | Asn | Cys | Thr | Ile |
A16V + S108N§ | Val | Asn | Cys | Asn | Ile | |||
N51I + S108N | 7G8, It.D12 | MR | MR | Ala | Ile | Cys | Asn | Ile |
C59R + S108N | K1, V1 | MR | MR | Ala | Asn | Arg | Asn | Ile |
N51I + C59R + S108N | W2 | HR | MR | Ala | Ile | Arg | Asn | Ile |
C59R + S108N + I164L | Cs1-2 | HR | HR | Ala | Asn | Arg | Asn | Leu |
N51I + C59R + S108N + I164L | V1/S | HR | HR | Ala | Ile | Arg | Asn | Leu |